graham hughes - beta technology - fp 7 call presentation
DESCRIPTION
TRANSCRIPT
Technology Strategy BoardDriving Innovation
FP7 2012 Health CallOverview
Graham Hughes, FP7UK NCP for Health (Industry)
Technology Strategy BoardDriving Innovation
“FP7 work programmes will “continue to secure world excellence in basic research” through large scale
collaborative research efforts
JM Barroso 2009
Technology Strategy BoardDriving Innovation
FP7 - €53 billion spend 2007 - 2013
Technology Strategy BoardDriving Innovation
Cooperation Theme
Technology Strategy BoardDriving Innovation
Cooperation Theme Basics
• Top down process, yearly call for proposals based around specific topic areas
• Projects performed by consortia of academic/industry/ public sector participants
• Matched funding (EU contributes to total cost of project)• Participants sign legal contract with the EU
Technology Strategy BoardDriving Innovation
Three Major Objectives
•Improve the health of European citizens
•Boost the competitiveness of health related industries
•Address global health issues
Also seeking to implement research objectives that help to realise the aims of the Innovation Union (Europe 2020) flagship initiative .
Health Theme Objectives
Technology Strategy BoardDriving Innovation
The Health Theme: Structure
Activity 1:Biotechnology, generic tools & technologies for health
Activity 2:Translating research for
human health
Activity 3:Optimising the delivery of health care
cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender-related health issues
Activity 4: Support actions & response to policy needs
The Innovative Medicines Initiative
Technology Strategy BoardDriving Innovation
Health Theme Funding 2007 - 2013
YearTotal
FundingProjects Funded
2007€641
million153
2008€577
million172
2009€611
million105
2010€621
million131
2011€650
million~126
2012€620
million?
2013€780
million?
Technology Strategy BoardDriving Innovation
UK Performance (Health Theme)
Health Funding totals 2007 -2009 – All Participations
Technology Strategy BoardDriving Innovation
UK FP7 Health Theme in Numbers*Submissions with UK partners = 3264*Successful projects with UK partners = 859
UK coordinated submissions = 38393 projects coordinated by UK partners
*2007 – 2009 data – from GAs and participants database (released on 1 May 2010 - data cut-off date 25 March 2010
52 UK SMEs in active FP7 projects (plus 17 new 2010)
Technology Strategy BoardDriving Innovation
SME Participation
EU target of 15% funding to SME partners
Technology Strategy BoardDriving Innovation
Access significant research funding• 75% RTD costs and 100% management and training costs• EU contribution between €2 and 12 million• Overhead rate for HEIs and SMEs = 60%
Strengthening Research Capabilities• Increased collaboration between basic and clinical researchers,
regulatory bodies and patient groups
Access to new networks and contacts• develop new business contacts from the linkages formed in a
consortium• Access to IP and facilities otherwise unavailable
Elevated Profile• Publications, CORDIS
Collaborative Research: Why?
Technology Strategy BoardDriving Innovation
Collaborative Research: Who?
Countries•EU Member States – broadest rights and access•Associated Countries – e.g. Iceland, Norway, Turkey, Israel•International Cooperation Partner Countries (ICPC) – e.g. Russia, Central Asian, Balkan, North African countries•Industrialised high-income countries (e.g Australia, Korea, Japan) – self financing. USA has reciprocal arrangement•Co-operation with “third countries” explicitly encouraged in FP7
Organisations•research groups at universities or research institutes•innovative companies (SMEs and larger)•public or governmental administration (eg NHS trusts) •Charities and other not for profit organisations
Technology Strategy BoardDriving Innovation
• Build consortium :– 3 legal entities from minimum of 3 EU Member states or
Associated Countries– Other partners added per requirements of
project/partner mix – Some other special eligibility criteria may apply – read
call document carefully
• Match project with the topic– Seek advice if not sure– Funding level is indicative of project scope – Pay attention to expected outcome – European scope
• Follow rules for submission (EPSS)
Collaborative Research: How?
Technology Strategy BoardDriving Innovation
WP First Draft Open day
(Brussels) 09 June 2011
Call published
Stage 1 Deadline
NCP Roadshow
Evaluation results
Evaluation
PC Meetings
Collaborative Research: When?
Technology Strategy BoardDriving Innovation
Framework Programme 7Support and Further Information
Graham Hughes, FP7UK NCP for Health (Industry)
Technology Strategy BoardDriving Innovation
Initial Considerations
Are you ready for participation?– Does it fit your aspirations/business plan– Collaborative projects mean working alongside international
partners. • Does this suit you way of working?• Can you pull together or find a consortium?
– Funding is highly competitive, prepare to be disappointed– Do you want to lead a project? (Time/resource)– Is the level of funding appropriate?– Can you wait 1 year for the money?
Technology Strategy BoardDriving Innovation
Key Tips
• Competition is fierce – must be well over the threshold to succeed
• Remember the European aspect• Read the call carefully – seek 2nd and 3rd opinions on
topic fit• Write simply and clearly – don’t assume expert
knowledge• Make time to do a good job – avoid last minute
submissions• Seek help early on
Technology Strategy BoardDriving Innovation
Support and Further Information
Technology Strategy BoardDriving Innovation
• Informing and Awareness Raising– Call documents and supporting information– Website and printed newsletters, e-bulletins– Promotional activities – info days, seminars, – Signposting – other themes + funding schemes
• Advising and Training– Helpline – e-mail and telephone enquiries– Partner search– Direct support
• Feedback and Signposting– Problems or difficulties during implementation or participation– Direct contact with EU Scientific Officers– Identifying and communicating other areas of support and funding
NCP Support
All advice is impartial, confidential and free
Technology Strategy BoardDriving Innovation
Support and Further Information
Website https://ktn.innovateuk.org/web/fp7uk
E mail [email protected]
Phone 01302 322633
Mobile 07775 584028
Alternative
+44 (0)20 7395 2205
Technology Strategy BoardDriving Innovation
Framework Programme 72012 Call Information
Graham Hughes, FP7UK NCP for Health (Industry)
Technology Strategy BoardDriving Innovation
2012 Call – Context
Innovation Union•research and innovation are key drivers of competitiveness, jobs, sustainable growth and social progress.
•More topics targeting knowledge generation to deliver innovative products, processes and services.
•Challenge led programme focusing on specific issues
•More emphasis on exploitation issues such as dissemination, IP protection and knowledge generation.
Technology Strategy BoardDriving Innovation
2012 Call – Innovation Driven
• Challenge driven – fewer areas open, multiple projects in each area. (36 topics total)– Primary focus is European Innovation Partnership initiative on
active and healthy ageing– Aim to mobilise critical mass of resources and implement
coherent set of actions – Interlinked topics to bring in wide range of inputs
• Balance upstream research and activities closer to market to achieve short and medium-term outcomes– focus on medical technologies– address the socio-economic challenge of innovation
Technology Strategy BoardDriving Innovation
2012 Call – Closed Areas
1.1 High Throughput Research
1.3 Suitability, Safety and Efficacy of Therapies*2.2.1 Brain and Brain Related Diseases
2.3.1 Anti Microbial Drug Resistance
2.3.3 Potentially New and Re-emerging Epidemics
2.3.4 Neglected Infectious Diseases*
2.4.1 Cancer
2.4.2 Cardiovascular Disease
3.1 Translating the Results of Clinical Research Outcome
3.3 Health Promotion and Prevention
4.2 Responding to EU Policy Needs
Technology Strategy BoardDriving Innovation
2012 Call Overview
• SME Focus – many SME targeted topics and new SME Call
• Active and Healthy Ageing – 9 coordinated topics
• Medical Technologies – feature highly (related to SME focus)
• Other areas of focus:Rare Diseases
Clinical Trials
Personalised and Regenerative Medicine (inc transplantation)
Systems Biology and -omics
HIV/AIDS, Malaria and TB
Healthcare delivery
Coordination and Support Activities
Technology Strategy BoardDriving Innovation
2012 Call – SME Focused
• Two stage submission/evaluation • Several funded proposals per topic• Technology/Methods based topics• Open topic descriptions• Small – medium sized projects
– €3m or €6m EC contribution– 2 – 5 year duration
• SME targeted topics– 10 Minimum 30% of EC contribution to SMEs– 6 Minimum 15% of EC contribution to SMEs
> 30%
>15%
Technology Strategy BoardDriving Innovation
Health Theme Funding 2007 - 2013
YearTotal
FundingProjects Funded
SME Targeted
2 Stage
2007€641
million153 0% 0
2008€577
million172 0% 0
2009€611
million105 0% 0
2010€621
million131 0% 19%
2011€650
million~126 20% 75%
2012€620
million? 53% 100%
2013€780
million? ~ 50% 100%
Technology Strategy BoardDriving Innovation
2012 Call – Pilot SME Innovation Call
• 3 topics only:– 1,4-2: Medical Technology for transplantation and bioartificial organs
– 2.3.0-1: Diagnostics for infectious diseases in humans
– 2.4.5-1: Technological approaches to combating sensory impairments
• SMEs have leading role in the project• >50% EU funding goes to SME partners• # participants limited (3 – 5)• All partners from EU MS or ACs • Limits on project duration • Accelerated evaluation and grant negotiation timeline
> 50%
Technology Strategy BoardDriving Innovation
2012 Call – Research Priorities#1 Ageing
Must meet Europe 2020 objectives of active and healthy ageing:
– Healthy, active and independent lives until old age– Ensure the sustainability and efficiency of social and healthcare systems– Create a European/Global market for innovative products and services related to
healthy and active ageing
11 Topics in call are linked to EIP initiative
Cross thematic initiative: ICT,KBBE + SSH
EIP
Technology Strategy BoardDriving Innovation
2012 Call – Research Priorities#2 Medical Technologies
• Supporting the “innovation” strategy and closer to market approach
• Large overlap with “SME friendly” topics
• 9 topics through the work programme Tech
Technology Strategy BoardDriving Innovation
2012 Call – Research Priorities#3 Clinical Trials
•Continue the initiative started in the 2011 call for investigator driven clinical trials
– Improve quality of clinical trials data in Europe
– Strengthen CTs in Europe in areas with unmet medical needs
•Funding for Stage II,III or IV clinical trials as RTD activities (i.e. 75% EC contribution). Flexibility w.r.t. duration and participation.•Involvement of patient groups encouraged•Outsourcing possible
– Subcontracted third party– Reimbursement on cost basis
Clin
Technology Strategy BoardDriving Innovation
1.2: Detection, Diagnosis and Monitoring
1.2.1Development of technologies with a view to patient group stratification for personalised medicine applications
6,000,000 >1
EIP
> 30%
• Support R&D and/or proof of principle of technologies for application in the area of personalised medicines
• Tailored medical interventions• More effective• Fewer undesirable side effects
• Technologies should be of use for research, screening, diagnostics and/or guidance on therapeutic interventions
Technology Strategy BoardDriving Innovation
1.4: Innovative Therapeutic Approaches and Interventions
1.4-1 Innovative approaches to solid organ transplantation 6,000,000 >1
1.4-2 Medical technology for the transplantation sector and bioartificial organs 6,000,000 >1
1.4-3* Innovative strategies for translation of stem cell based therapies in regenerative medicine 6,000,000 1
1.4-4 Targeted nucleic acid delivery as an innovative therapeutic or prophylactic approach 6,000,000 >1
>15%
>15%
EIP
> 50%
> 30%
Tech
Tech
* 1.4-3 requires cooperation with Australia
Clin
Transplantation topics have not featured highly in FP7 to date
Technology Strategy BoardDriving Innovation
2.1.1: Large Scale Data Gathering
2.1.1.1-A Support for international rare disease research 2,000,000 1
2.1.1.1-B Clinical utility of -omics for better diagnosis of rare diseases 12,000,000 2
2.1.1.1-C Databases, biobanks and clinical bio-informatics' hub for rare diseases 12,000,000 1
2.1.1-2 Validation of -omics based biomarkers for diseases affecting the elderly 12,000,000 >1
2.1.1-3 Statistical methods for collection and analysis of -omics data 6,000,000 >1 >15%
EIP
> 30%
> 30%
• Objective is to use high-throughput technologies to generate data for elucidating the function of genes and gene products.
• Topics focus on the clinical use of –omics approaches and analysis of their outcomes.
Technology Strategy BoardDriving Innovation
2.1.2: Systems Biology
• medical needs should drive systems biology research• using systems medicine to improve understanding of disease
mechanisms, prognosis and diagnosis of common diseases• Coordinate European research activities for systems biology
applications to medicine
2.1.2-1 Systems medicine: SME-driven research applying systems biology approaches to address clinical needs 3,000,000 >1
2.1.2-2Systems medicine: Applying systems biology approaches for understanding common human diseases and their co-morbidities
12,000,000 >1
2.1.2-3 Preparing for the future research and innovation activities in systems medicine 3,000,000 1
> 30%
Technology Strategy BoardDriving Innovation
2.2.2: Human Development and Ageing
2.2.2-1Integrative systems biology and comparative genomics for studying human ageing and most common age-related conditions
6,000,000 >1
2.2.2-2Investigator-driven clinical trials for optimisation of treatment for elderly patients with multiple diseases
6,000,000 >1>15%
EIP
EIP
Clin
> 30%
• Focus on use and application of –omics knowledge and tools to gain a clear understanding of the fundamental mechanisms of human ageing
• Clinical trials should compare outcomes of various treatment regimens
Technology Strategy BoardDriving Innovation
2.3.0: Cross Cutting
2.3.0-1 Diagnostics for infectious diseases in humans 6,000,000 >1
2.3.0-2 ERA-NET on Infectious Diseases 2,000,000 1
> 50%
Tech
• SMEs should take a leading role in 2.3.0-1• Project should be < 3 years • €6,000,000 ceiling is max only
• ERA-NET should deepen and extend the coordination of European research in infectious diseases and be complementary to other European activities in this area.
Technology Strategy BoardDriving Innovation
2.3.2: HIV/AIDS Malaria and TB
• Co-infection and co-morbidity of HIV and other common infectious diseases poorly understood
• Prevention topic is looking for small, rapid projects o 1 – 3 years, €1 – 6 million funding
• Low cost interventions looking for solutions that can be implemented within the project period
2.3.2-1 Co-infection and co-morbidity in HIV/AIDS, malaria, tuberculosis and/or hepatitis 6,000,000 >1
2.3.2-2 Co-morbidity between infectious and non-communicable diseases 6,000,000 >1
2.3.2-3 Prevention and treatment for HIV/AIDS, malaria and tuberculosis 6,000,000 >1
2.3.2-4 Low-cost interventions for disease control in resource poor settings 3,000,000 >1
>15%
Technology Strategy BoardDriving Innovation
2.4.3: Diabetes and Obesity
2.4.3-1 Innovative approach to manage diabetes 6,000,000 >1
2.4.3-2 Investigator-driven clinical trials for type 1 diabetes research 6,000,000 >1
Clin
> 30%
Tech
Technology Strategy BoardDriving Innovation
2.4.4: Rare Diseases
2.4.4-1Preclinical and/or clinical development of substances with a clear potential as orphan drugs
6,000,000 >1
2.4.4-2 Observational trials in rare diseases 3,000,000 >1
2.4.4-3 Best practice and knowledge sharing in the clinical management of rare diseases 2,000,000 1
Clin
Clin
> 30%
Technology Strategy BoardDriving Innovation
2.4.5: Other Chronic Diseases
2.4.5-1 Technological approaches to to combating sensory impairments 6,000,000 >1
2.4.5-2 Biomarkers and diagnostics for chronic inflammatory diseases of the joints 6,000,000 >1
EIP
> 50%
>15%
EIP
Tech
Tech
Technology Strategy BoardDriving Innovation
2012 Call – Healthcare Delivery
• Addressing the need for systematic mapping of variations in health care practice and standardisation of health technology assessment
• Various areas of healthcare covered• EU has strong political stance on healthcare equality
3.2-1 Improving the organisation of health service delivery 3,000,000 >1
3.2-2 New methodologies for health technology assessment 3,000,000 >1
3.2-2 Social Innovation platform for ageing research 6,000,000 1
3.4-1 Health systems/services research in low and middle income countries 6,000,000 >1
EIP
EIP
Tech
Technology Strategy BoardDriving Innovation
2012 Call – Coordination and Support Actions
• Various actions to complement research activities, develop infrastructure and determine future activities
4.1-1Network to encourage technology transfer in FP-funded health research (especially in academic and governmental organisations)
2,000,000 1
4.1-2 Training actions linked to intellectual property rights management and technology transfer 2,000,000 1
4.1-3Support for Presidency events: Organisation of supporting actions and events related to the Presidency of the European Union
100,000 >1
4.1-4 Communicating the benefits of European research to the general public 1,000,000 >1
4.1-5 Preparing for the future for health research and innovation 500,000 >1
Technology Strategy BoardDriving Innovation
09 June 2011: Open Info Day, Brussels
10 June 2011: Brokerage Event, Brussels
20 July 2011: Call Opens – EPSS available
27 Sept 2011: likely Stage 1 deadline (INNOVATION 2)
04 Oct 2011: likely Stage 1 deadline (INNOVATION 1)
Dec 2011: Stage 1 notification
Feb 2012: Stage 2 deadline
Key Dates
Technology Strategy BoardDriving Innovation
Other Health Related EU Funding Sources 2011
Nanosciences, Materials and Production NMP
NMP.2012.1.2-2: Development and phase-I clinical trials of novel therapeutic nanotechnology-enabled systems for the diagnosis and treatment of atherosclerosis
NMP.2012.2.2-1: Biomaterials for improved performance of medical implants
Likely timeframe similar to Health call
Technology Strategy BoardDriving Innovation
Other Health Related EU Funding Sources 2011
ICT call•Virtual Physiological Human•E-health and data management
KBBE call
Research For the Benefit of SMEs •Call opens July 2011
Ambient Assisted Living•ICT based solutions for Advancement of Older Persons’ Mobility•Call opened 31 March 2011, deadline 30 June 2011